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ABSTRACT
Amoebiasis is an infection caused by Entamoeba histolytica and is a potential health risk in countries 
in which health barriers are inappropriate. Since the discovery of Entamoeba dispar, the prevalence 
of amoebiasis has been modified. Objective: This study has standardized the PCR technique applied 
for the diagnosis of different species of the E. histolytica/E. dispar complex and has evaluated the 
prevalence of infection among patients attending private and public clinical laboratories in Salva-
dor City, Bahia State, Brazil. Results: Analysis of 52,704 stool samples by microscopic examination 
demonstrated that 1,788 (3.4%) were positive for the E. histolytica/E. dispar complex and infection 
occurred more often in samples originated from public clinical laboratories (5.0%) than those that 
came from private laboratories (3.2%). PCR performed in approximately 15% (262) E. histolytica/ 
E. dispar complex positive samples, randomly chosen, amplified 227 samples (86.6%), all of them 
positive for E. dispar. The non-amplified 35 samples (13.4%) were also negative for E. histolytica-spe-
cific galactose adhesin. Moreover, to exclude a probable infection caused by E. hartmanni, morpho-
metric analysis demonstrated that non-amplified samples had cyst sizes comparable to E. histolytica/ 
E. dispar (>10 µm). Conclusion: The absence of amplification of these samples indicates the presence 
of PCR inhibitors in the stool samples or the presence of DNA from Entamoeba species other than 
E. dispar, E. histolytica or E. hartmanni.
Keywords: amebiasis; Entamoeba histolytica; diagnosis; prevalence.
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INTRODUCTION
Parasitic infections are endemic and represent 
a major public health problem in developing 
countries.1-6 In particular, Entamoeba histo-
lytica, the etiologic agent of amoebic colitis 
and liver abscess, causes human infections on 
a global scale, resulting in significant human 
suffering and death. Approximately 50 million 
people have this invasive disease annually, re-
sulting in 100,000 deaths per year and making 
this the second most common cause of para-
sitic death in humans.7 The high prevalence of 
infection is due to fecal contamination of food 
and water supply; thus, the disease is predomi-
nantly seen in developing countries.8
E. histolytica cysts measure 10-15 µm in 
diameter, possess a rigid cyst wall and can 
contain up to four nuclei. They are morpho-
logically indistinguishable from cysts of the 
commensal Entamoeba dispar and share char-
acteristics with cysts of Entamoeba hartmanni, 
which are smaller than 10 µm in diameter. Op-
tical microscopy is a desirable tool for the di-
agnosis of amoebiasis:9 it is simple and cheap 
to execute and does not require sophisticated 
technology. However, microscopy is unable to 
differentiate between species belonging to the 
E. histolytica/E. dispar complex. Moreover, in-
termittent releasing of cysts decreases the sen-
sitivity of this method. Therefore, the positivity 
rate is enhanced by the use of concentration 
procedures, one of which is formalin-ether sed-
imentation.10 Concentrated and purified cysts 
of E. histolytica/E. dispar can improve diagnos-
tic sensitivity to differentiate E. histolytica from 
E. dispar by polymerase chain reaction (PCR), 
especially in feces that contain low numbers of 
cysts. The coproantigen ELISA technique has 
been suggested for use in routine diagnostic 
procedures and epidemiological studies. How-
ever, PCR is used for final confirmatory identi-
fication of intestinal amoebiasis.11-14
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The prevalence of the E. histolytica/E. dispar complex 
differs among the five regions of Brazil with 2.5-11% in 
the South and Southeast, 19% in the North and the Ama-
zon region and approximately 10% in the Northeast and 
Midwest.4,15 This variation in prevalence is associated with 
regional differences in sanitation and socio-economic con-
ditions, mainly related to housing, sewage facilities, water 
quality, and other as yet unknown factors.16
Given the medical importance of differentiating species 
that belong to the E. histolytica/E. dispar complex and the 
fact that the prevalence of each species is unknown in Salva-
dor City, the purpose of this study was to perform a survey 
to determine the prevalence of E. histolytica and E. dispar 
using a nested and multiplex PCR technique with genomic 
DNA extracted from stool specimens of individuals resi-
dents in Salvador City. 
MATERIALS AND METHODS
Sample details
A total of 52,704 stool samples were collected from pa-
tients attending Datalab and NKB-Bahia groups (private 
clinical laboratories, n = 47,080) and the Clinical Labora-
tory of Pharmacy Faculty and University Hospital, Univer-
sidade Federal da Bahia (public clinical laboratories, n = 
5,624), from February to August 2006. A single fresh stool 
specimen was collected from each patient, and diagnosis 
of the E. histolytica/E. dispar complex was performed by 
the spontaneous sedimentation technique.17 Daily, around 
8-15 samples were positive for E. histolytica/E. dispar com-
plex. From these, 262 samples were randomly selected for 
cysts concentration and extraction of genomic DNA. Ap-
proximately 800 mg of each positive sample was preserved 
without fixative and stored at -20° C for immunologic di-
agnosis. 
This study was carried out in Salvador City (Bahia State, 
Northeast Brazil), which has a population of 2,892,625 in-
habitants,18 and was approved by Committee of Ethics in Re-
search of the Gonçalo Moniz Institute number 100/2006. In-
formed consent for participation was obtained from patients 
(or legal guardians in the case of minors) during collection 
of clinical specimens. A form for personal (age, sex) and 
epidemiologic data (e.g., race, signs and symptoms, drugs) 
was completed for all patients positive for E. histolytica/ 
E. dispar complex.
The sample was estimated for different scenarios based 
on the following parameters: error α = 0.05 and power of 
test (1–β) = 0.90, minimum detectable odds ratio (OR) = 2.0 
and frequency of exposure 3.2%, according to Santos et al.19
Cyst concentration and morphometric analysis
To concentrate the cysts of these parasites, 25 E. histolytica/ 
E. dispar-positive samples were used to test the efficiency of 
spontaneous sedimentation, formalin-ether and flotation 
by zinc sulfate or sucrose.20 The cysts were concentrated 
from 5 g of fresh stools as described by Troll et al.21 Ap-
proximately 25 µL of the concentrated sample and 50 µL of 
iodine were mixed, spotted on glass slides and covered by 
a coverslip (24 x 24 mm). The slides were analyzed by 40 x 
magnification, and the average of cysts was quantified in 20 
microscopic fields.
Morphometric analysis of cysts was performed us-
ing reticule calibration in a millimeter scale (mm). Each 
0.01 mm corresponded to 10 µm in cyst size. 
Extraction of genomic DNA
Cysts purified from 5 g of fresh stools by the formalin-
ether technique were used for DNA extraction. A 50 µL 
pellet was washed four times with distilled water at 2,000 
x g for 30s in an Eppendorf microfuge. The pellet was re-
suspended in a small volume (50 - 100 µL) of a solution 
containing 100 mM Tris, pH 8.0, and 2.5 mM EDTA. The 
tubes were immersed in a mixture of dry ice and ethanol 
for 4 min and incubated at 50°C for 3 min. This process was 
repeated six times to rupture the cysts. The samples were 
then sonicated three times by being immersed in picked 
ice in an ultrasonic cleaner (model 250, Branson Sonifier, 
USA) for 30s at an amplitude of 35 without pulses. Then, 
200 µL of buffer containing 100 mM Tris (pH 8.0), 1% so-
dium dodecyl sulfate, 25 mM EDTA and 200 µg of pro-
teinase K (Boehringer, Mannheim, Germany) was added 
to each tube, mixed, incubated at 50°C for 24h, boiled for 
10 min and centrifuged at 12,000 x g for 5 min. The DNA 
in the supernatant was precipitated with 360 µL ice-cold 
isopropanol, resuspended with 20 µL of 10 mM Tris and 
1 mM EDTA and frozen for analysis by PCR.
Multiplex PCR
Nested and multiplex PCR was carried out according to 
the protocol described by Evangelopoulos et al.,12 with 
some modifications. A set of oligonucleotide primers 
based on small subunit rDNA (SSU-rDNA) sequences 
of E. histolytica and E. dispar were prepared. The outer 
primer set, E1 (5’-TGC TGT GAT TAA AAC GCT-3’) 
and E2 (5’-TTA ACT ATT TCA ATC TCG G-3’), which 
specifies a 1,076-bp fragment, is common to and specifi-
cally designed for both species. The inner primer pair for 
pathogenic sequences, Eh-L (5’-ACA TTT TGA AGA 
CTT TAT GTA AGT A-3’) and Eh-R (5’-CAG ATC TAG 
AAA CAA TGC TTC TCT-3’), brackets a 427-bp region, 
whereas the inner primer pair Ed-L (5’-GTT AGT TAT 
CTA ATT TCG ATT AGA A-3’) and Ed-R (5’-ACA CCA 
CTT ACT ATA CCT ACC-3’) is specific for E. dispar, re-
sulting in a 195-bp fragment.
Amplification was performed in a total volume of 
50 µL containing 0.5 µM of each primer, 5 µL 
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Table 1. Comparison of four techniques for concentration of amoeba cysts
Cysts Methodology Mean number of cysts in 40X p*
  (Microscopic field) 
E. histolytica/E. dispar complex Spontaneous sedimentation 1.72 0.02 
 Formalin-ether 5.88 - 
 Flotation by sulfate zinc 0.72 < 0.001 
 Flotation by sucrose 0.64 < 0.001
E. coli Spontaneous sedimentation 5.71 0.008 
 Formalin-ether 44.18 - 
 Flotation by sulfate zinc 13.59 0.021 
 Flotation by sucrose 9.82 0.01
The cysts were concentrated from 5 g of fresh stools with a positive diagnosis for E. histolytica/E. dispar or E. coli. The analysis 
of statistical significance between differences in numbers of cysts concentrated by formalin-ether or other methodologies was 
performed using the Wilcoxon Test. 
10X PCR buffer (200 mM Tris-HCl, pH 8.4, 500 mM 
KCl), 0.2 mM of each dNTP, 1.5 mM MgCl2, 0.75U Taq 
DNA polymerase (Gibco BRL, Rockville, MD) and 3 µL 
of DNA sample. An initial DNA amplification was per-
formed using the E1, E2 primer set in a GenAmp PCR 
system 2400 (AB Applied Biosystems) thermal cycler. 
The first cycle of 5 min at 94°C was followed by 45 cy-
cles of denaturation for 1 min at 94°C. Primers were an-
nealed for 1.5 min at 47° C and elongated for 2.5 min at 
72°C. As positive controls, 5 µL of DNA from cultured 
E. histolytica strain HM-1:IMSS, grew in TYI-S-33 medium 
axenically, and 5 µL of DNA from cultured E. dispar strain 
MCR, grew in Pavlova medium polyxenically (kindly pro-
vided by Dr. Maria Aparecida Gomes, Amoebiasis Labo-
ratory, Universidade Federal de Minas Gerais, Brazil) were 
used. For subsequent amplifications, 5 µL of DNA from the 
first reaction and primer sets Eh-L, Eh-R and Ed-L, Ed-R 
were used under the conditions described above, except that 
the annealing temperature was 58°C. The analysis of PCR 
products was performed using gel electrophoresis. DNA 
fragments were separated on a 1.5% (w/v) agarose gel (Inv-
itrogen Life Technologies, USA) containing 0.5 µg ethidium 
bromide/mL. Gels were photographed under ultraviolet il-
lumination (Sigma Chem. Co., USA, model T1201).
Immunoenzymatic assay
The presence of E. histolytica-specific galactose adhesin 
was determined in 35 stool samples, without preservatives, 
that were negative by PCR and 60 randomly selected stool 
samples that were positive for E. dispar. The ELISA test was 
performed according to the manufacturer’s instructions 
(TechLab E. histolytica II ELISA, USA). 
Statistical analysis
The statistics tests used in this study were performed using 
the SPSS program 15.0 for Windows. The Wilcoxon test was 
used to evaluate the statistical significance between analyzed 
variables; a two-tail p-value less than 0.05 was considered 
significant.
RESULTS
Cyst concentration
The effects of spontaneous sedimentation, formalin-ether 
and flotation by sulfate zinc or sucrose on the concentration 
of cysts of the E. histolytica/E. dispar complex were evalu-
ated. The formalin-ether technique yielded more cysts than 
any other method analyzed with a mean of 5.88 cysts un-
der 40 x magnification, varying from 0.1 to 8 cysts (Table 1). 
The mean number of E. histolytica/E. dispar complex cysts 
by formalin-ether was 3.42 (p = 0.02), 8.17 (p < 0.001) 
and 9.19 (p < 0.001) times more than that of the sponta-
neous sedimentation, zinc sulfate and sucrose flotation 
procedures, respectively. Likewise, the formalin-ether tech-
nique concentrated 7.73 (p = 0.008), 3.25 (p = 0.021) and 
4.5 (p = 0.01) times more cysts of Entamoeba coli than the 
above mentioned techniques. Statistically significant dif-
ferences between other concentration methods were not 
 observed (p > 0.05).
Amplification of DNA extracted from stool samples
The standardization of nested and multiplex PCR was per-
formed using DNA from cultured trophozoites of E. histol-
ytica strain HM-1 and E. dispar strain MCR. The detection 
limit was determined by the addition of 100 µL of stools free 
Santos, Gonçalves, Soares
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Figure 1. Limit detection of Multiplex-PCR in detection of 
DNA from E. dispar. Amplified PCR products using Eh-R/
Eh-L and Ed-L/Ed-R primers and a 1.5% electrophoresis gel 
stained by ethidium bromide. M, molecular weight lad-
der (100-bp ladder); Lane 1, negative control (presence of 
primer dimer); Lane 2, positive control (PCR products from 
12 ng/mL DNA from E. histolytica – 427 bp); Lane 3, posi-
tive control (PCR products from 18 ng/mL DNA from 
E. dispar – 195 bp); Lane 4, PCR products from 9 ng/mL DNA 
from E. dispar; Lane 5, PCR products from 4.5 ng/mL 
DNA from E. dispar; Lane 6, PCR products from 2.25 ng/mL  DNA 
from E. dispar ; Lane 7, PCR products from 1.12 ng/mL DNA from 
E. dispar.
Figure 2. Evaluation of inter-testing reproducibility. Am-
plified products in a 1.5% electrophoresis gel stained by 
ethidium bromide. PM, molecular weight ladder (100-bp 
ladder); Lane 1, negative control; Lane 2, positive control (DNA 
of E. histolytica – 427 bp); Lane 3, positive control 
(DNA of E. dispar – 195 bp); Lanes 4 to 9, clinical sample 
positive for E. dispar amplified monthly during a period 
of six months; Lane 10, clinical sample negative for the 
E. histolytica/E. dispar complex (presence of primer dimer).
Figure 3. Evaluation of intra-testing reproducibility. Ampli-
fied products in a 1.5% electrophoresis gel stained by ethid-
ium bromide. M, molecular weight ladder (100-bp ladder); 
Lane 1, negative control (presence of primer dimer); Lane 2, 
positive control (DNA of E. histolytica – 427 bp); Lane 3, posi-
tive control (DNA of E. dispar – 195 bp); Lanes 4 and 5, clinical 
samples spiked with 3.0 ng/mL of DNA from the HM-1 strain 
of E. histolytica; Lanes 6 and 7, clinical samples positive for 
E. dispar; Lane 8, clinical sample negative for the E. histolytica/E. 
dispar complex.
Table 2. Prevalence of E. histolytica/E. dispar in 
laboratories from Salvador-BA
                                    Samples
Laboratories Total (n) Positives (%)
Not public 47,080 1,507 (3.2%)
Datalab 25,996 984 (3.8%)
Dirceu Ferreira 18,501 473 (2.6%)
Qualitech 2,583 50 (1.9%)
Public 5,624 281 (5.0%)
HUPES1 2,078 86 (4.1%)
Pharmacy School (UFBA)2 3,546 195 (5.5%)
Not public + public 52,704 1,788 (3.4%)
1Professor Edgard Santos University Hospital. 
2Universidade Federal da Bahia.PM 1 2 3 4 5 6 7 8 9 10
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of parasites to either different concentrations of E. histol-
ytica DNA (12 ng/mL, 6 ng/mL, 3 ng/mL, 1.5 ng/mL and 
0.75 ng/mL; data not shown) or different concentrations of 
E. dispar DNA (18 ng/mL, 9 ng/mL, 4.5 ng/mL, 2.25 ng/mL 
and 1.12 ng/mL; Figure 1). Multiplex PCR was capable of 
detecting the specific target sequence when a minimum of 
1.5 ng/mL of DNA template was used for E. histolytica and 
when 2.25 ng/mL was used for E. dispar.
A positive stool sample for the E. histolytica/E. dispar 
complex was fractionated into six aliquots and stored at 
-20°C. At monthly intervals, one aliquot was thawed, and its 
DNA was used to observe the inter-testing reproducibility 
of the PCR (Figure 2). Compatible profile bands are shown 
with the species of amoeba tested. Similar results were ob-
tained when the samples were amplified twice in the same 
reaction to demonstrate the reproducibility of intra-testing 
of PCR, as shown in Figure 3. 
Analyses of stool samples
Analyses of 52,704 stool samples by microscopic examina-
tion demonstrated that 3.4% (1,788) of the samples were 
positive for the presence of four-nucleus amoebae. Of these 
stool samples, 47,080 were from private clinical laborato-
ries, and 5,624 were from public clinical laboratories. Ac-
cording to the source of samples, the prevalence of the E. 
histolytica/E. dispar complex was 3.2% (1,507) and 5% (281) 
in the private and public laboratories, respectively (Table 2).
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Figure 4. Analysis of 262 E. histolytica/E. dispar positive sam-
ples by Multiplex-PCR. Amplified PCR products using Eh-R/
Eh-L and Ed-L/Ed-R primers and a 1.5% electrophoresis gel 
stained by ethidium bromide. M, molecular weight ladder (100-
bp ladder); Lane 1, negative control (presence of primer dimer); 
Lane 2, positive control (DNA of E. histolytica – 427 bp); Lane 3, 
positive control (DNA of E. dispar – 195 bp); Lanes 4 to 6, clinical 
samples spiked with 3 ng/mL of DNA from the HM-1 strain of 
E. histolytica; Lanes 7 and 8, clinical samples positive for 
E. dispar; Lane 9, negative sample for the E. histolytica/E. dispar 
complex.
Extraction of DNA from 262 samples positive for the 
E. histolytica/E. dispar complex followed by PCR showed 
that 227 samples (86.6%) were positive for E. dispar, as dem-
onstrated by amplification of the species-specific fragment 
(195 bp). No amplification was observed for pathogenic 
E. histolytica. To evaluate the efficiency of detecting E. histolyt-
ica fragments, we spiked negative samples with DNA template 
from E. histolytica strain HM-1:IMSS. Thereafter, the E. histo-
lytica DNA fragment (495 bp) was amplified from all samples. 
This demonstrates that nested and multiplex PCR can be used 
for both E. histolytica and E. dispar species (Figure 4).
The mean number of cysts found in amplified samples 
was 116 cysts per gram of stool, while the mean number 
of cysts in the 35 non-amplified samples was 173 cysts. 
After successive dilution (1:20 to 1:160), these 35 samples 
remained negative. Even after having carried out the spike 
technique the samples did not amplify. In order to resolve 
this problem, non-amplified samples and 60 randomly cho-
sen samples positive for E. dispar by PCR were submitted 
to an E. histolytica-specific galactose adhesin immunoenzy-
matic assay. This technique demonstrated that all 35 non-
amplified samples were negative for E. histolytica-specific 
galactose adhesin, suggesting a high PCR specificity in 
E. histolytica diagnosis. Furthermore, to distinguish a prob-
able infection caused by E. hartmanni, morphometric analy-
sis demonstrated that non-amplified samples had cyst sizes 
comparable to E. dispar (> 10 µm).
Characteristics of E. dispar infection
The mean age of the 262 E. histolytica/E. dispar com-
plex-positive individuals submitted to amplification re-
actions was 35.7 years (with a range of 2 to 79 years), 
and the median was 35 (25 and 75% quartiles were 
22.5 and 50, respectively). Sixty-four percent were male, 
and 65.5% were of African descent (p < 0.005), with 
a monthly income of less than 5 minimum wages 
(p < 0.005) and an educational level at the 2 grade (p < 0.005).
The study population was asymptomatic or pre-
sented non-specific symptoms that could be attributed 
to amoebiasis. The primary reason for seeking medical 
attention was routine medical check-up, as reported by 
67.2% of participants. Among the cases, 21.3% report-
ed having gastrointestinal disturbances, flatulence and 
diarrhea, 11.5% reported using metronidazole, and no 
confirmation of E. histolytica infection. We identified 
31 individuals with liquid stool samples (12% samples) 
and none with mucus or blood in their stools. A total of 
45 individuals (17%) had loose stool samples, and 186 
(71%) had formed stool samples.
DISCUSSION AND CONCLUSION
In this report, we described a PCR-based technique for 
selective identification of E. histolytica and E. dispar in 
stool samples. The technique consists of an initial am-
plification of a 1,076-bp fragment of the SSU-rDNA se-
quence of both species, followed by an additional ampli-
fication for the two species differentiation. This multiplex 
PCR permits specific identification in a single reaction 
mixture and is therefore more cost-effective and less la-
borious than other PCR-based methods.12 Some studies 
have shown methods used to isolate DNA from in vitro 
amoeba cultures.5,27,28 However, the cultivation of amoe-
bae before concentrating cysts is more expensive and 
time-consuming.29 Here, we isolated DNA for PCR am-
plification of amoeba DNA directly from the stools, re-
ducing time and the possibility of false negative results.
However, PCR presents some disadvantages. It can 
be difficult to purify DNA from stool samples due to 
hardness of the cyst wall and the presence of inhibiting 
substances, which can inhibit the Taq polymerase.13,30-32 
According to Campos-Górgora et al.,33 the major com-
ponent of the Entamoeba cyst wall is chitin, a homopol-
ymer of beta-(1,4)-linked N-acetyl-D-glucosamine that 
confers great rigidity and resistance. Therefore, the uti-
lization of both chemistry and physical conditions was 
sufficient to yield a great quantity of genetic material to 
proceed with the PCR.
Until now, there had not been an ideal method for 
extracting Entamoeba DNA from feces because various 
substances could act as inhibitors.34,35 In fact, inhibition 
Santos, Gonçalves, Soares
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occurred in 13.3% of samples. It is likely that non-spe-
cific substances inhibited amplification, since the num-
ber of cysts found in these samples did not influence the 
reaction and the presence of non-specific substances in 
feces, indirectly evaluated by spike, showed that added 
DNA did not suffer similarly in amplification of succes-
sive dilutions. Specific column chromatography could 
minimize the influence of enzymatic inhibitors present 
in feces. According to Verweij et al.,13 it is fast and sim-
ple to use. The authors observed that only 1.7% of 657 
samples could not be amplified by PCR. We observed an 
inhibition in 13.3% of our samples, and the utilization 
of the columns might have lowered this figure. However, 
specific column chromatography use increases the cost 
of PCR, making this technique impracticable in labora-
tory diagnosis.
In 1997, it was formally accepted that the species once 
called E. histolytica comprises two distinct species: the 
potentially invasive E. histolytica and the non-invasive, 
commensal E. dispar.7 The cysts and trophozoites of 
these species cannot be distinguished microscopically. 
As no inexpensive or practical diagnostic procedures are 
currently available for the identification of E. histolytica 
at health centers in countries with limited resources, 
we are left with the common practice of identifying the 
E. histolytica/E. dispar complex as “E. histolytica.” The 
likely consequence of this is over-diagnosis and over-
treatment, which could be the cause of anti-amoebic 
drug resistance.22 Therefore, a method capable of differ-
entiating both species is essential for appropriate treat-
ment and follow-up of infected individuals.
As a result, there has been a lot of progress in 
the search for molecular methods to distinguish E. 
histolytica/E. dispar complex species in the last few 
decades. Coproantigen searching, for example, has in-
numerable advantages relative to other methodologies. 
However, antigens can denature during the preservation 
process, yielding false negative results. Another alterna-
tive to differentiating the species is PCR. This technique 
has been used frequently in epidemiological investiga-
tions worldwide.5,23-26
In this report, the prevalence of E. histolytica/E. 
dispar based on fecal examination by optical micros-
copy was 3.4%. This finding corroborates the results 
in the literature that state that the prevalence of in-
fection varies a great deal throughout Brazil, reach-
ing 19% in the Amazon and varying from 2 to 29.5% 
in other regions.4,15,16,36 In the present study, the analy-
sis of 262 samples with E. histolytica/E. dispar using 
specific set of primers showed that 227 (86.6%) were 
positive for E. dispar. No amplification was observed 
in 35 samples (13.4%) that were negative for E. histo-
lytica-specific galactose adhesin. Moreover, to exclude a 
probable infection caused by E. hartmanni, morphometric 
analysis demonstrated that non-amplified samples had cyst 
sizes comparable to E. histolytica/E. dispar (> 10 µm). The 
absence of amplification of these samples indicates 
the presence of PCR inhibitors in the stool samples or the 
presence of DNA from Entamoeba species other than E. dis-
par, E. histolytica or E. hartmanni.
In fact, Oliveira-Costa et al.37 in Belo Horizonte City, 
Southeast Brazil, and Dourado et al.38 in Pernambuco 
State, Northeast Brazil, described only the presence of E. 
dispar in their studies. Santos et al.5 found a prevalence 
of 21% for four-nucleus amoebae in two slums in Rio 
de Janeiro State, Southeast Brazil, but only two samples 
were positive for E. histolytica. It appears that E. histol-
ytica is more common in North and extreme Northeast 
Brazil and is rare in other regions.4,39
Our described protocol provides a method to sen- 
sitively and selectively detect and diferentiate 
E. histolytica and E. dispar DNA directly from stool 
specimens without the need for prior cultivation. Apart 
from often unsuccessful and time-consuming cultiva-
tion attempts, possible misdiagnoses by one strain dis-
placing the other in mixed infections can be avoided. 
We believe that difficulties in the differential diagnosis 
of the E. histolytica/E. dispar complex need to be over-
come for the adequate treatment of E. histolytica. PCR is 
expensive, and the majority of laboratories do not have 
adequate infrastructure for its use. The utilization of 
this method in Brazil is in its initial phase and restricted 
to research centers located in big cities. However, once 
the method is established and standardized, its cost will 
decrease. The main limitations to this technique are the 
difficulty in obtaining conserved DNA from cysts, and 
the presence of unspecific inhibitors. More inquiries 
about simpler, faster and cheaper methodologies should 
be encouraged and, after approval, should be established 
in laboratories that compose the public and private 
health network.
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